[Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].
Low molecular weight (LMW) heparin Kabi 2165 possesses improved pharmacodynamic properties compared with conventional heparin. It is currently investigated in the prophylaxis of thromboembolism. The neutralization of Kabi 2165 by protamine chloride was analysed after i.v. injection of both the agent and the antidot in healthy persons. The anticoagulant effects of the LMW heparin on the activated partial thromboplastin time, thrombin, and thromboelastography are completely and immediately suppressed by protamine chloride. The inhibition of factor Xa is antagonized up to 50%-60%. The bleeding time remained unaffected. The data indicate that protamine chloride may be used in clinical situations as an antidot to the LMW heparin Kabi 2165. A rebound phenomenon of the anticoagulant effect does not occur.
D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D005170:Factor X / Q000037:antagonists & inhibitors; D015951:Factor Xa; D006493:Heparin / Q000494:pharmacology*; D006494:Heparin Antagonists / Q000494:pharmacology*; D006801:Humans; D008970:Molecular Weight; D011479:Protamines / Q000494:pharmacology*; D013916:Thrombelastography
D006494:Heparin Antagonists; D011479:Protamines; D005170:Factor X; D006493:Heparin; D015951:Factor Xa
Neutralisierung von niedermolekularem Heparin Kabi 2165 mit Protaminchlorid.